Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Response to Restriction/Election
Applicant’s election of without traverse of Group I, claims 1-15, in response to restriction requirement of 11/25/2025 is acknowledged. Applicant’s election without traverse of the following species is also acknowledged:
PNG
media_image1.png
116
556
media_image1.png
Greyscale
Therefore, claims 16-17 are withdrawn from further consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. Applicants preserve their right to file a divisional on the non-elected subject matter.
Status of the claims
Claims 1-15 are examined on merits in this office action.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-15 are rejected under 35 U.S.C. 103 as being unpatentable over Takeuchi et al (Chem. Commun. 2018).
In regards to claim 1, Takeuchi is directed to molecularly imprinted polymer (MIP) nanoparticles (Page 6344, lines 5-6 of 2nd col. and page 6245, lines 16-18 or 2nd col.). Takeuchi teaches molecularly imprinted polymer (page 6245, 1st para of 2nd col.) having a molecularly imprinted cavity (Fig 2 ) having sensing capability (page 6246, 2nd para of 2nd col.) for biological material (e.g. protein; page 6245, 2nd para of 2nd col.). Takeuchi discloses molecularly imprinted polymer particle having cavity wherein the molecularly imprinted polymer comprises a constituent unit derived from a functional monomer having a functional group comprising a group that interacts with the biological material and a signal binding group that is different from the group that interacts with the biological material:
PNG
media_image2.png
401
770
media_image2.png
Greyscale
(Fig. 9).
In the above scheme, the functional monomer utilized is
PNG
media_image3.png
132
336
media_image3.png
Greyscale
, which comprises a functional group (carboxylic group) that interacts with biological material and the secondary amine group (PIM site shown by dotted circle) is considered a signal binding group (i.e. capable of binding to a fluorescent group) that is different from the carboxylic group, which interacts with the biological material. See the above scheme wherein the secondary amine is utilized for binding to fluorescent group FITC.
Takeuchi teaches molecularly imprinted polymer (MIP) (Page 6344, lines 5-6 of 2nd col. and page 6245, lines 16-18 or 2nd col.) but, however, does not mention the MIP having the functional monomer
PNG
media_image3.png
132
336
media_image3.png
Greyscale
as nanoparticle. However, from the description of Takeuchi of MIP nanoparticles for use as drug-delivery system (page 6344, lines 5-6 of 2nd col.) and molecularly imprinted polymer nanoparticles for a bisphenol A (BPA)-sensing system (page 6245, lines 16-18 of 2nd col.) throughout the reference, one of ordinary skilled in the art can easily envisage the MIP having the
PNG
media_image3.png
132
336
media_image3.png
Greyscale
as nanoparticles for various sensing systems with a reasonable expectation of success because Takeuchi discloses MIP nanoparticles for BPA-sensing system.
In regards to the recitation “for sensing use” in the preamble, it is an intended use language and Applicant is reminded that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. See In re Casey, 152 USPQ 235 (CCPA 1967) and In re Otto, 136 USPQ 458, 459 (CCPA 1963).
In regards to claim 2, as described above, Takeuchi discloses functional group
PNG
media_image3.png
132
336
media_image3.png
Greyscale
, wherein the carboxylic group represents R1 that interacts with the biological material,
PNG
media_image4.png
45
64
media_image4.png
Greyscale
represents L1 and the
PNG
media_image5.png
91
162
media_image5.png
Greyscale
having the secondary amine group (drawn withing the circle) represents R2 comprising the signal substance binding group.
In regards to claim 3, as disclosed above, Takeuchi discloses carboxyl group that binds with the biological materials.
In regards to claim 4, as described above, the secondary amine group shown withing the dotted circle is the signal substance binding group.
In regards to claim 5, as described above, Takeuchi discloses functional group
PNG
media_image6.png
92
193
media_image6.png
Greyscale
, which reads on chemical Formula 2 wherein R11 is carboxylaryl group, the CH2 group linking the aryl group to the secondary amine NH represents L11 as an alkylene.
In regards to claim 6, Takeuchi discloses FITC (i.e. a signal group) bound to the signal substance binding group NH as disclosed in Fig. 9:
PNG
media_image7.png
125
136
media_image7.png
Greyscale
.
In regards to claim 7, Takeuchi discloses functional group
PNG
media_image3.png
132
336
media_image3.png
Greyscale
(4-[2-(N-methacrylamido)ethylaminomethyl]
benzoic acid (MABA)), which is considered as a constituent unit derived from N-substituted (meth)acrylamide.
In regards to claims 8 and 9, Takeuchi discloses human serum albumin (HSA) interacting with COOH group in the binding cavity (Fig. 8).
In regards to claims 10-13, the recitations “for sensing use of claim 1, which is used ..” recited in claim 10, “for sensing use of claim 1, wherein the biological material is a substance……” recited in claim 11, “the sensing use of claim 11, wherein the membrane structure is a cell, ………” recited in claim 12 and “for sensing use of claim 1, wherein the biological material is ……….”, are all directed to intended use language of utilizing the nanoparticle and are not a part of the claimed nanoparticle structures.
Applicant is reminded that a recitation of the intended use of the claimed invention, must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. Where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation. See Bell Communications, 55 F.3d at 620; Kropa v. Robie, 38 C.C.P.A. 858, 187 F.2d 150, 152, 88 USPQ 478, 481 (1951). “Where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation". Rowe v. Dror, 112 F.3d 473, 478, 42 USPQ2d 1550, 1553 (Fed. Cir. 1997.
In regards to claim 14, Takeuchi teaches immobilized MIP nanoparticle having fluorescent group and interacting carboxylic group on sensor chip substrate (page 6246, 1st para of 2nd col.) and thus various disclosed MIP nanoparticles including the MIP nanoparticle having FITC and arylcarboxylic group as described above, on a chip substrate surface or on various other substrate surface for detection would be obvious to one of ordinary skilled in the art.
In regards to claim 15, the claimed reagent only comprises the nanoparticle of claim 1 and thus the disclosed nanoparticle of Takeuchi reads on the claim.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAFIQUL HAQ whose telephone number is (571)272-6103. The examiner can normally be reached on Mon-Fri 8-4:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gregory S. Emch can be reached on 571-272-8149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SHAFIQUL HAQ/Primary Examiner, Art Unit 1678